UNSPSC 51383401: Acemetacin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H18ClNO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5V141XK28X, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester but generally known as acemetacin, which bears US NIH Compound Identifier 1981. European Medicines Agency schedules Acemetacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05209MIG.

UNSPSC 51383401 Acemetacin is a Commodity code nominally focused on a specific nonsteroidal anti-inflammatory drug, but state and local procurement activity under this code does not consistently align with acemetacin procurement. Instead, recent opportunities tagged to this code reflect a broader spectrum of pharmaceutical and health-related products, including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. The issuing bodies range across county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Work solicited includes emergency response pharmaceuticals, community health initiative supplies, generic pharmaceutical distribution agreements, and direct-to-manufacturer prescription program development. This misalignment between the code's nominal scope and actual procurement activity suggests the code may be used as a catch-all for pharmaceutical purchasing rather than reserved strictly for acemetacin products.

Recent activity appears concentrated in the Southeast and Upper Midwest, with Seminole County, Florida, Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) among recent soliciting bodies. The Seminole County IFB60459723LAS (IFB due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, using competitive bidding with a two-year initial term and one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager and wholesaler channels, signaling early-stage procurement planning rather than immediate award activity. MMCAP's RFP S1070000015802, due March 26, 2026, established multistate contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026, and a two-year initial term plus optional extensions. Given the code's sparse and thematically scattered recent activity, this Commodity code warrants monitoring for clearer pharmaceutical procurement patterns rather than immediate pursuit.